Androgens and the breast by Dimitrakakis, Constantine & Bondy, Carolyn
Available online http://breast-cancer-research.com/content/11/5/212
Page 1 of 9
(page number not for citation purposes)
Abstract
Androgens have important physiological effects in women while at
the same time they may be implicated in breast cancer pathologies.
However, data on the effects of androgens on mammary epithelial
proliferation and/or breast cancer incidence are not in full
agreement. We performed a literature review evaluating current
clinical, genetic and epidemiological data regarding the role of
androgens in mammary growth and neoplasia. Epidemiological
studies appear to have significant methodological limitations and
thus provide inconclusive results. The study of molecular defects
involving androgenic pathways in breast cancer is still in its infancy.
Clinical and nonhuman primate studies suggest that androgens
inhibit mammary epithelial proliferation and breast growth while
conventional estrogen treatment suppresses endogenous
androgens. Abundant clinical evidence suggests that androgens
normally inhibit mammary epithelial proliferation and breast growth.
Suppression of androgens using conventional estrogen treatment
may thus enhance estrogenic breast stimulation and possibly
breast cancer risk. Addition of testosterone to the usual hormone
therapy regimen may diminish the estrogen/progestin increase in
breast cancer risk but the impact of this combined use on
mammary gland homeostasis still needs evaluation.
Introduction
Treatment of women with physiological testosterone
supplementation to remedy hypoactive sexual desire disorder
is an area of great interest at present [1]. While it seems
evident that testosterone treatment increases sexual activity,
the risk-benefit ratio for such treatment remains unclear.
Androgen receptors are found in virtually every tissue in
women as well as men, including breast, bone and brain,
indicating that androgens and their metabolites may play an
important role in normal tissue homeostasis and possibly in
pathologies like breast cancer, osteoporosis, libido and
cognitive decline. Thus, testosterone treatment to improve
sexual function may have unintended effects in diverse
tissues. A continuing area of concern is the notion that
excess androgen exposure may increase the risk of breast
cancer in women [2].
Experimental data suggest that conventional estrogen
treatment regimens, both as oral contraceptives (OCs) and
hormone therapy (HT) [3], upset the normal estrogen/
androgen balance and promote ‘unopposed’ estrogenic
stimulation of mammary epithelial proliferation and, hence,
potentially breast cancer risk. This is due to suppression of
gonadotropins by exogenous estrogen treatment, resulting in
globally reduced ovarian steroidogenesis, so both
endogenous estrogen and androgen production are reduced,
but only estrogens are provided by the treatment regimens.
Additionally, estrogens, particularly in oral form, stimulate the
hepatic production of sex hormone binding globulin (SHBG),
which binds testosterone with high affinity, reducing
androgen bioavailability. As a result of this dual effect, total
and bioavailable testosterone levels are significantly reduced
in women taking oral contraceptives or estrogen supplemen-
tation for ovarian insufficiency [4].
This literature review compares the findings that androgens in
women promote the risk for breast cancer versus the
evidence that androgens protect the mammary gland from
hormone-induced stimulation, increased proliferation and
neoplasia.
Normal breast development: estrogens and
androgens
Estrogens stimulate, while androgens inhibit breast develop-
ment independently of genetic sex. Breast tissue is similar in
prepubertal boys and girls. Pubertal rises in estrogen levels
cause breast growth in girls and frequently in boys
(transiently). Estradiol levels are significantly higher in girls
with premature thelarche than in normal prepubertal girls. An
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association between expression of a high activity isoform of
the testosterone metabolizing CYP3A4 and the early onset
of thelarche has been documented, suggesting that
decreasing testosterone levels may also trigger early breast
growth [5]. Conversely, androgen excess due to adrenal
tumor or hyperplasia suppresses normal breast develop-
ment in girls, despite apparently adequate estrogen levels
[6]. In castrated male-to-female transsexuals, feminizing
estrogen therapy stimulates breast growth with full acinar
and lobular formation and estrogen-treated genetically male
breast tissue exhibits normal female histology. Estrogens
taken to treat prostate cancer also lead to breast
development in men with suppressed gonadal function and
reduced testosterone levels. Conversely, androgen use by
female athletes and female-to-male transsexuals leads to
breast atrophy.
Supporting the normal inhibitory role of endogenous
androgens on breast growth, androgen receptor (AR) blockade
with flutamide causes gynecomastia and rarely breast adeno-
carcinoma [7]. Males may also develop gynecomastia when the
estrogen/androgen ratio is increased due to decreased
androgen production or increased aromatization.
The balance between stimulatory effects of the estrogens and
inhibitory effects of the androgens is the critical factor that
regulates mammary cell proliferation both in normal and in
cancer tissues [8]. It has not been possible to identify
specific estrogen/androgen ratios predictive of breast
stimulation or inhibiting effects for several reasons. Estradiol
and testosterone assays have not been very sensitive nor
accurate in the lower ranges, while both hormones bind to
SHBG, so total values may not be as informative as ‘free’ or
bioavailable hormone [4]. Moreover, single hormone
measurements may not be very informative about tissue
exposure over time. Both estradiol and testosterone levels
vary hourly in response to diurnal rhythm, diet, stress and
exercise, so a single value may be inadequate to assess true
tissue exposure. In addition, estradiol and testosterone may
be synthesized locally in peripheral tissues from circulating
precursors such as the sulfate of dehydroepiandrosterone
(DHEA-S) and androstendione [9]. The conjugated products
of steroid metabolism find their way into the circulation after
peripheral action and provide evidence as to the proportion of
the precursor pools of steroids utilized as androgen or
estrogen. Analysis of these metabolites by Labrie and
colleagues [9] and Sasano and colleagues [10] suggested
that the major proportion of androgen effectors in women
derive from such an endocrine mode of action, which will not
be detected by assays of circulating testosterone or
dihydrotestosterone (DHT). Interestingly, while circulating
levels of testosterone and DHT are five- to ten-fold higher in
men than women, the abundance of androgen metabolites is
less than two-fold higher in men, suggesting that local tissue
production and action of androgens in women may be more
significant than historically suspected.
The mammary gland is capable of synthesizing both estradiol
and testosterone. All the steroidogenic enzymes necessary
for the formation of androgens and estrogens from steroid
precursors - steroid sulfatase, 17β-hydroxysteroid dehydroge-
nases (17β-HSDs), 3β-HSDs, 5α-reductases and aromatase -
have been reported in normal mammary tissues, breast
cancer specimens or cell lines [10]. Androgens stimulate or
inhibit the growth of breast cancer cells in vitro depending on
the cell line and clone under study according to former data
[11]. Breast cancer cell lines and tissue specimens express
the enzymes involved in DHT as well as estradiol synthesis. In
a histochemical study, expression of 5α-reductase was
significantly correlated with androgen receptor expression
and 17β-HSD and 3β-HSD immunoreactivities and the
abundance of this androgenic molecular assembly was
inversely correlated with tumor size, histological grade and
proliferative index [12], suggesting an inhibitory role for DHT
in tumor growth.
Androgen receptor
Androgen agonists such as testosterone and DHT function
through binding to the intracellular AR. This is a member of
the nuclear hormone receptor super-family comprising classic
DNA-binding, hormone binding and activation domains
(Figure 1). AR expression is abundant in normal mammary
epithelium and in the majority of breast cancer specimens
and cell lines. The AR is co-localized with estrogen and
progesterone receptors in epithelial cells but not detected in
mammary stroma or myoepithelium [13]. The co-expression of
estrogen receptor (ER) and AR in mammary epithelial cells
suggests that the effects of estrogen and androgen on
mammary epithelial proliferation are integrated within the
mammary epithelial cell. The AR gene is located on the X
chromosome with no corresponding allele on the Y, so it
functions solely as a single copy gene, as shown by the
complete loss of androgen effect in XY individuals with an
inactivating mutation of the AR [14].
Binding of testosterone or DHT triggers a cascade of signa-
ling events, including phosphorylation and conformational
changes in the receptor, which dissociates from cytoplasmic
proteins and migrates to the cell nucleus. Ligand-activated
AR regulates gene expression through binding to androgen
response elements located in a gene’s enhancer or promoter
region. As with other similar receptors, the AR functions in
transcriptional regulation in concert with a host of nuclear
proteins, which may serve as co-activators or co-repressors.
Interestingly, the BRCA1 gene product has been identified as
an AR co-activator [15]. The BRCA1 protein binds to the AR
and potentiates AR-mediated effects, suggesting that
BRCA1 mutations may blunt androgen effects. However,
other studies have not confirmed these findings [16].
AR has a highly polymorphic CAG repeat in exon 1 that
encodes a polyglutamine stretch (Figure 1). There is evidence
that longer CAG repeats are associated with earlier age ofbreast cancer onset [16]. However, other studies have not
confirmed this finding [17]. In a study nested within the
Nurses’ Health Study cohort [18], no relation was found
between AR genotype and breast cancer risk among post-
menopausal Caucasian women overall, but an increased risk
was observed when analysis was limited to those individuals
with a first-degree family history of breast cancer. Germ-line
mutations in the AR gene conferring variable degrees of
androgen insensitivity have been associated with the
occurrence of breast cancer in men [19]. Another study [20]
provides evidence that the association with the long AR-CAG
was observed only in postmenopausal and not premeno-
pausal women, which may explain the insignificant results in
studies restricted to young women. In other studies, reduced
risk was observed with another trinucleotide repeat, GGC, in
young women. AR repeat length might be partly responsible
for the increased risk of early onset breast cancer in women
using oral contraceptives or HT [21].
Emphasis should be given to the fact that none of these
studies had sufficient statistical power to implicate or exclude
specific AR defects in breast cancer risk. A recent epidemio-
logical meta-analysis concludes that there is no association
between AR genetic variations and breast cancer risk among
Caucasian women [17].
AR-CAG repeat length was inversely associated with testos-
terone levels in both pre- and postmenopausal normal women
[22]. Lillie and colleagues [23] evaluated the association
between AR-CAG repeat length and mammographic density,
a strong breast cancer risk factor. They found that in
postmenopausal estrogen/progesterone users, carriers of the
less active AR had a higher mean percentage of density than
carriers of the more active AR. This suggests that AR
genotype modifies hormone-induced proliferation as reflected
in mammographic density and explains the mechanism by
which estrogen/progesterone use increases breast cancer
risk. However, the exact mechanisms and metabolic paths in
which AR participates in normal tissues are still obscure. The
role of AR in oncogenesis or breast tumor proliferation
remains unclear. It is possible that the steroid receptor
contributes differently in healthy compared to cancerous
breast tissue; thus, a number of unanswered questions
remain and further studies are needed before safe conclu-
sions are drawn.
The hypothesis that androgens are directly involved in breast
carcinogenesis is based on the presence of ARs in the
majority of breast cancers. It is proposed that androgens,
through binding to their receptors, act independently to
produce tumors with specific clinical behaviors [24]. Clinical
data support that a significant number of poorly differentiated
breast carcinomas are ER-negative and progesterone
receptor (PR)-negative but AR-positive, or patients with AR-
positive tumors experience a better disease-free survival.
These associations constitute important clinical and
pathologic prognostic information. Recently, AR expression in
a tumor is considered as an indicator of lower malignancy
potential; this provides a new range of therapeutic targets for
poorly differentiated cancers [25].
Androgens and breast cancer:
epidemiological data
Long-term estrogen treatment increases the risk of breast
cancer in both males and females through estrogenic
stimulation of mammary epithelial proliferation. Additional
carcinogenic effects by estrogen metabolites have been
proposed [26]. The most widely accepted risk factor for
breast cancer is the cumulative dose of estrogens that breast
epithelium is exposed to over time. However, it has been
difficult to correlate breast cancer risk with isolated serum
estrogen levels in epidemiological studies, probably secon-
dary to problems using single random hormone levels for the
evaluation of tissue-specific exposure as discussed above.
Attempts to correlate adrenal precursor steroids with breast
cancer incidence have been relatively successful, or at least
consistent, perhaps reflecting the importance of local tissue
conversion. Many years ago, reduced 17-ketosteroid excre-
tion was noted in the urine of pre-menopausal women with
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Figure 1
Schematic design of the androgen receptor gene (top) and protein (below). The polymorphic trinucleotide repeat site (CAG) is indicated in green
at the left. Trans-activating function (TAF), DNA-binding (DBD) and ligand-binding domains (LBD) are labeled.breast cancer and subsequent studies have documented
reduced DHEA and its sulfate (DHEA-S) in the serum of pre-
menopausal breast cancer patients. In the first prospective
study in this field, levels of androgen metabolites in urine
were found to be abnormally reduced in premenopausal
women who subsequently developed breast cancer [27],
indicating a protective role of androgens on the breast. In
contrast, in a recent prospective study of pre-menopausal
women [28], no association was found between plasma
adrenal androgen levels and risk of breast cancer. In the
Nurses’ Health Study II, no correlation between DHEA and
DHEA-S levels and breast cancer risk overall was found but,
interestingly, among premenopausal women there was a
positive association, especially for tumors that express both
ERs and PRs [29]. Also, among premenopausal women,
higher levels of testosterone and androstendione were
associated with increased risk of invasive ER+/PR+ tumors,
although with a non-statistically significant increase in overall
risk of breast cancer [29].
Several epidemiological studies have examined the correla-
tion of circulating androgens, such as testosterone, and risk
for breast cancer. A major limitation of these studies was that
the androgen assays used were developed primarily to
measure the higher levels found in men and lack reliability in
the low ranges found in normal women [4]. Testosterone and
androstenedione levels demonstrate substantial daily
variability, while most of the epidemiological data are based
on a single blood sample collected at non-standard times.
Another problem using serum testosterone levels to gauge
androgenic effects at the tissue level is that most of the
circulating testosterone is tightly bound to SHBG, while only
the free hormone is bioactive. SHBG, and thus total testos-
terone levels, vary widely based on genetic, metabolic and
endocrine influences, and it is now accepted that measure-
ment of free or bioavailable testosterone predicts androgenic
effects more accurately than total testosterone levels [4].
Finally, most androgenic activity in women originates from the
peripheral conversion of precursors such as DHEA into
androgens within the cells of target tissues, and this activity
will not be detected by measurement of circulating androgens.
In a recent study [30], levels of testosterone and DHEA-S in
saliva were statistically significantly lower in breast cancer
patients compared to controls and these differences were
more profound in postmenopausal women. Breast cancer
patients, when compared to controls, presented with an
androgen insufficiency and a relative imbalance of sex steroid
hormones in favor of estrogens.
Several studies have revealed, however, that adrenal andro-
gens are increased in postmenopausal women with breast
cancer [31]. A possible explanation regarding the divergence
between pre- and postmenopausal findings is that one
adrenal ‘androgen’, androstenediol, also known as ‘herma-
phrodol’, is a weak ER agonist. In the presence of high
estrogen levels in premenopausal women, androstendiol
could exhibit anti-estrogenic effects, while in the hypo-
estrogenic postmenopausal milieu, the agonist effect may
predominate. This view remains speculative, and other
possibilities still exist. It is possible that the high estrogen
environment in premenopausal women promotes androgenic
enzyme and AR expression in mammary tissue, allowing
androgenic effects by DHEA metabolites, while in postmeno-
pausal women, an estrogen-deficient tissue microenviron-
ment may favor estrogenic effects.
Genetic variation in CYP19 and SHBG genes was found to
contribute to the variance in circulating hormone levels in
postmenopausal women, but none was statistically signifi-
cantly associated with breast cancer risk [32].
In some prospective epidemiological studies, age-adjusted
mean values of total and free testosterone and estradiol were
significantly higher pre-diagnostically in postmenopausal
breast cancer cases compared with controls, and estradiol
and total testosterone were elevated in other case-control
studies of postmenopausal breast cancer. It was observed
that elevated serum levels of both estrogens and androgens
contribute to a greater risk of breast cancer [33] and a meta-
analysis of nine prospective studies revealed that breast
cancer risk increases with increasing concentrations of
almost all sex hormones [34].
None of these studies manage, however, to disconnect the
risk associated with increased estradiol levels from the
androgen component, and since androgens are the obligate
precursors for estradiol synthesis, this is a major confounding
factor in assessing the role of androgen independently of the
known cancer-promoting estrogen effect. In line with these
observations, a recent study [35] concluded that increased
breast cancer risk with increasing body mass index among
postmenopausal women is largely the result of the associated
increase in estrogens. The association of androgens with
breast cancer risk did not persist after adjustment for estrone,
the estrogen most strongly associated with the risk. Other
authors conclude that conversion of DHEA to estrogens,
particularly estradiol, is required to exert a mitogenic
response [36]. These results suggest that the contribution of
androgens to breast cancer risk is largely through their role as
substrates for estrogen production.
Other studies have found no association between androgens
and breast cancer [37,38]. Recent epidemiological studies
on the association between androgen levels and breast
cancer risk are summarized in Table 1.
The above mentioned observations indicate the difficulty
separating potential direct effects of circulating testosterone
from its potential to be aromatized into estradiol. An interesting
research topic would be to investigate levels of testosterone
and DHT metabolites in these studies in order to assess more
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serum hormone measurement seems unlikely to be informative
about a woman’s true long-term exposure to that hormone or
her specific risk of developing breast cancer. Nor does it seem
to be a biologically plausible mechanism that androgens acting
as androgens could promote breast cancer, since virtually all
clinical data suggest just the opposite. If elevated androgen
levels directly contribute to breast cancer, then women with
clinically evident long-term hyperandrogenism - for example,
polycystic ovary syndrome and congenital adrenal hyperplasia -
should experience increased rates of breast cancer, but this is
not the case [39]. Moreover, androgen levels are chronically
elevated in men, who have a breast cancer risk less than 1% of
that of women. This is despite the fact that lifetime estradiol
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Table 1
Epidemiological studies on the association between androgens and breast cancer risk
Study Conclusion
Elevated levels of androgens (and estrogens) are associated with increased risk of breast cancer
Tamimi et al. 2006 [47] Prospective cohort study in Nurses’ Health Study with over a million person-years studied: women receiving 
postmenopausal hormones with testosterone had a 17.2% increased risk of breast cancer per year of use
Micheli et al. 2007 [54] Breast cancer patients (n = 194) with high testosterone had significantly lower event-free survival than those with 
low testosterone (P = 0.004) and a significantly higher risk of breast cancer events with an adjusted hazard ratio 
of 1.77 (95% CI, 1.06 to 2.96)
The Endogenous Hormones  Meta-analysis: breast cancer risk increases statistically significantly with increasing concentrations of almost all 
and Breast Cancer  sex hormones 
Collaborative Group 2002 [34]
Tworoger et al. 2006 [31] Prospective nested case-control study within the Nurses’ Health Study II: adrenal androgens are positively 
associated with breast cancer among predominately premenopausal women (for example, for DHEA: RR, 1.6; 
95% CI, 0.9 to 2.8; P = 0.09) 
Eliassen et al. 2006 [29] Nurses’ Health Study II, nested: higher levels of testosterone and androstenedione in 18,521 premenopausal 
women are associated with insignificant overall increase in breast cancer risk, but increased risk of invasive and 
ER+/PR+ cancers (for example, RR = 2.9; CI = 1.4 to 6.0) 
Androgen levels acting with protective patterns
Hofling et al. 2007 [51] Randomized, double-blind, placebo-controlled study: testosterone use inhibited exogenous estrogen-induced 
breast tissue proliferation in 99 postmenopausal women (P < 0.001) 
Dimitrakakis et al. 2004 [48] Retrospective, observational study that followed 508 postmenopausal women receiving testosterone in addition 
to usual hormone therapy: incidence of breast cancer in testosterone users was substantially less than in women 
receiving estrogen/progestin in the WHI study and in the Million-woman study
Suzuki et al. 2001 [55] Intratumoral dihydrotestosterone inhibits cancer cell proliferation in hormone-dependent human breast carcinoma
Haiman et al. 2002 [18] A case-control study nested within the Nurses’ Health Study cohort (cases, n = 727; controls, n = 969): longer 
CAG repeat alleles of AR increases breast cancer risk (odds ratio, 1.70; 95% CI, 1.20 to 2.40; P = 0.04)
MacLean et al. 2004 [19] Forty-one male breast cancers were studied: incidence of longer CAG repeats in AR was significantly higher in 
the breast cancer group than in the normal population (P < 0.05)
Ogawa et al. 2008 [25] In 227 primary breast cancers, AR expression was significantly higher in breast tumors with favorable 
characteristics 
Dimitrakakis et al. 2009 [30] Testosterone and DHEA-S salivary levels were statistically significantly lower in breast cancer patients compared 
to controls (n = 541)
No association between serum concentrations of androgens and breast cancer risk
Ness et al. 2009 [46] A group of postmenopausal participants in the WHI study used testosterone combined with estrogens: 
testosterone addition had no statistically significant effect on breast cancer occurrence
Cox et al. 2006 [17] Among postmenopausal women, common variants of the AR gene are not associated with risk of breast cancer
Page et al. 2004 [28] Prospective observational study: no relationship between serum DHEA or DHEA-S and subsequent breast 
cancer in middle-aged women
Olson et al. 2007 [32] No association with breast cancer risk was detected for individual variants of CYP19 mutation in 750 cases
Adly et al. 2006 [37] Serum levels of steroids in 331 women: androgen levels were not independently associated with increased risk of 
breast cancer
Beattie et al. 2006 [38] Case-cohort design including 135 postmenopausal women with and 275 without breast cancer enrolled in the 
NSABBP P-1 trial: risk of breast cancer was not associated with sex hormone levels
AR, androgen receptor; CI, confidence interval; DHEA, dehydroepiandrosterone; DHEA-S, DHEA sulfate; ER, estrogen receptor; NSABBP,
National Surgical Adjuvant Breast and Bowel Project; PR, progesterone receptor; RR, relative risk; WHI, Women’s Health Initiative.levels are not much lower in men than in women. In fact,
decreased androgen levels found, for example, in Kleinefelter’s
syndrome and other hypogonadal syndromes increase the risk
of breast cancer in males [40]. Epidemiological studies in men
indicate that low urinary androsterone and serum free
testosterone levels are related to early onset of breast cancer, a
much higher relapse rate and a worse response to endocrine
therapy [41].
Hormone therapy and androgens
Exposure to endogenous and exogenous estrogens is thought
to contribute to increased breast cancer risk. Since the
introduction of combined OCs 40 years ago, many changes in
doses and their biochemical structures have taken place and
the possibility that OCs may increase the risk of breast cancer
has been the subject of intense research. Although many
epidemiological studies in the past have not linked OC use to
breast cancer risk, several more recent studies have found an
association, either overall or especially in subgroups of
women. A large meta-analysis on previously published studies
[42] calculated a small but significant increase in relative risk
of breast cancer (RR = 1.24) in current OC users while other
publications [43] have not associated current or former OC
use with an increased risk of breast cancer. However,
because pill users are young, this represents a very small
increase in absolute risk. It is not yet known if lower dose and
variable OC formulations are associated with a similar
increase in risk, making comparisons very difficult.
The bulk of the currently available evidence supports a causal
relationship between the use of HT and breast cancer. Recent
and long-term users of HT are associated with higher risk. The
effect of concurrent progestin use appears to further increase
risk above that with estrogens alone. The most important
randomized clinical trial providing information about this issue
is the Women’s Health Initiative (WHI) study [44] reporting
increased risk of breast cancer in women who took estrogen
plus progestin but not in women who took estrogen alone
[45]. The results from observational studies are generally
consistent with those of the WHI trial, reporting no significant
variation in the risk of breast cancer with use of different
estrogens, progestins, doses, or routes of administration.
A group of postmenopausal participants in the WHI study
used testosterone combined with estrogens. In this group,
testosterone addition for a period of a year had no statistically
significant effect on breast cancer occurrence, suggesting at
least that androgen induction did not increase the number of
breast cancer cases in this trial [46]. In the same study, rates
of breast cancer were lower in longer-term compared to
shorter-term users of estrogen plus testosterone. On the
other hand, in a prospective study of over a million person-
years with 24 years of follow-up within the Nurses’ Health
Study, current users of estrogen plus testosterone have
shown a 2.5-fold increased risk of developing breast cancer
compared to menopausal women who used estrogen-only
therapy or to women who never used postmenopausal
hormone formulations [47].
If androgens are protective against breast cancer as many
studies suggest, then conventional HT may promote breast
cancer not only by increasing estrogen exposure but also by
decreasing endogenous androgen activity. Oral estrogen
therapy reduces free androgens by stimulating hepatic
production of SHBG and through suppression of luteinizing
hormone, thus inhibiting ovarian androgen production [4].
Thus, institution of pharmacological estrogen therapy at
menopause may result in a drastic reduction in the
testosterone/estradiol ratio, which is normally maintained at
relatively high levels throughout a woman’s lifespan
(Figure 2).
Pertinent to these results, our published article [48] provides
important information about the addition of testosterone to
the HT regimen. In our evaluation of 508 postmenopausal
women in Australia receiving testosterone in addition to usual
HT, the incidence of breast cancer in testosterone users was
substantially less than in women receiving estrogen/progestin
in the WHI study and in the Million-woman study [49]. Breast
cancer rates in the testosterone users was closer to that
reported for HT never users, and their age-standardization
rate was the same as for the general population in South
Australia. These observations suggest that the addition of
physiological doses of androgen to OCs and HT could
protect the breast from ‘unopposed’ estrogenic effects.
Suppression of normal endogenous androgen may be an
adverse consequence of pharmacological estrogen therapy, if
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Figure 2
Average estradiol (E2) and testosterone (T) levels across the female
lifespan. Y-axis, level in picograms; X-axis, age in years. Dashed lines
predict changes in T and E2 hormone levels resulting from estrogen
replacement therapy (ERT) beginning at menopause.androgens are indeed protective against estrogen-induced
mammary proliferation. We have shown that addition of low
physiological doses of testosterone (producing serum levels
in the mid-normal range for women as well as rhesus
monkeys) to estrogen therapy in ovariectomized rhesus
monkeys significantly inhibits HT-induced mammary epithelial
proliferation [3] (Figure 3). Additionally, testosterone treat-
ment significantly reduced mammary epithelial estrogen
receptor expression, thus suggesting a potential mechanism
for the growth inhibitory effect. Moreover, we have found that
treatment of intact cycling monkeys with the AR antagonist
flutamide resulted in a significant increase in mammary
epithelial proliferation [3], adding to the burden of evidence
that endogenous androgens normally limit mammary prolifera-
tion and, hence, cancer risk. Other studies on primates also
suggest that inclusion of testosterone with estrogen/
progesterone use may counteract breast cell proliferation
[50]. In a recent randomized, double-blind, placebo-con-
trolled study, testosterone use inhibited exogenous estrogen-
induced breast tissue proliferation in postmenopausal women
[51]. There is also evidence that testosterone does not
influence mammographic breast density like conventional HT
[51,52]. The antiproliferative effects of androgens on breast
tissue may occur either indirectly, via downregulation of other
receptors like PRs, or directly, through breast AR stimulation.
Women, and particularly postmenopausal women, have been
treated with testosterone for female sexual dysfunction for
almost six decades. The exact biological role of androgens in
the restoration of libido in hypoactive sexual desire disorder in
females is still unclear. The main safety concern for women
who have undergone years of this therapy has been breast and
endometrial cancer risk related to androgens. In a recent trial of
814 sexually hypoactive women, the results for breast cancer
risk were inconclusive [1]. Nevertheless, current experience
does not confirm a positive correlation between testosterone
use and breast cancer occurrence; thus, androgens do have a
place in female sexual dysfunction treatment.
Conclusion
This review focuses on the role of androgens with regard to
breast growth and neoplasia. Measurement of circulating sex
Available online http://breast-cancer-research.com/content/11/5/212
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Figure 3
Mammary epithelial proliferation shown by Ki67 immunoreactivity (brown dots) in ovariectomized monkeys treated with (a) placebo (Con),
(b) estradiol (E2), (c) E2 and progesterone (P4), (d) tamoxifen (Tam) and (e) E2 and testosterone (T). (f) Quantification of the Ki67 proliferation
index. Proliferation is increased with E2 or E2 and P4 (E/P), while this increase is attenuated by the addition of T to E2 (E/T). All differences are
statistically significant when compared to the placebo group. Data from Zhou and colleagues [53].steroids and their metabolites demonstrates that androgen
activity is normally abundant in healthy women throughout
their entire lifetime. Epidemiological studies investigating
testosterone levels and breast cancer risk have major
theoretical and methodological limitations and do not provide
consensus. The molecular epidemiology of defects in
pathways involved in androgen synthesis and activity in
breast cancer hold great promise, but investigation of these is
still in the early stages. Clinical observations and experimental
data indicate that androgens inhibit mammary growth, and
they have been used in the past with success to treat breast
cancer. It is of concern that current forms of estrogen treat-
ment in OCs and for ovarian failure result in suppression of
endogenous androgen activity considering that the addition
of testosterone to the HT regimen ameliorates the stimulating
effects of estrogen/progestin on the breast. Research
addressing the role of androgens in breast cancer prevention
and the efficacy of hormonal supplementation with
physiological androgen to maintain estrogen/androgen ratios
typical of normal women is warranted.
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